"Remission Induction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic act or process that initiates a response to a complete or partial remission level.
| Descriptor ID |
D012074
|
| MeSH Number(s) |
E02.860
|
| Concept/Terms |
Remission Induction- Remission Induction
- Induction, Remission
- Inductions, Remission
- Induction of Remission
- Remission Inductions
|
Below are MeSH descriptors whose meaning is more general than "Remission Induction".
Below are MeSH descriptors whose meaning is more specific than "Remission Induction".
This graph shows the total number of publications written about "Remission Induction" by people in this website by year, and whether "Remission Induction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 5 | 5 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 3 | 4 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 6 | 6 |
| 2015 | 0 | 6 | 6 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 4 | 4 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 11; 81(11):1541-1548.
-
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022 07 12; 328(2):151-161.
-
Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. Pediatr Rheumatol Online J. 2021 Aug 30; 19(1):137.
-
Liposorber? LA-15 system for LDL apheresis in resistant nephrotic syndrome patients. Pediatr Nephrol. 2022 03; 37(3):585-592.
-
Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology. 2021 04; 160(5):1502-1520.e1.
-
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2020 12; 72(12):1800-1808.
-
Cortisol awakening response in PTSD treatment: Predictor or mechanism of change. Psychoneuroendocrinology. 2020 08; 118:104714.
-
Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. Aliment Pharmacol Ther. 2020 02; 51(3):364-373.
-
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
-
Complete resolution of primary cutaneous marginal zone B-cell lymphoma on the cheek of a 7-year-old boy with intralesional triamcinolone and tincture of time. Pediatr Dermatol. 2020 Jan; 37(1):228-229.